SELLAS Life Sciences Group, Inc. (SLS) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 2.27B USD. 52-week range 1.39 to 15.88 USD. Data as of 2026-10-09.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is ...